Although DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in AMI) trials reported that patients receiving insulin infusion had significantly lower rates of death compared with control groups, other studies including DIGAMI 2, HT‐5 (Hyperglycemia: Intensive Insulin Infusion in Infarction), and BIOMArCS‐2 (Randomized Trial to Evaluate the Clinical Value of Intensive Glucose Monitoring and Regulation in Myocardial Infarction) trials failed to find a persistent beneficial effect of intensive glucose‐lowing therapy.24, 25, 26, 27, 28. The gene discussed is INS; the disease is Hyperglycemia.